Proactive Investors UK - Axis-Shield develops anti-CCP rheumatoid arthritis test for Abbott Laboratories

1 year chart

1 day chart

Epic & Msn data
Epic	ASD
Time:	08:00:31
Mid Price:	392.00
Change Today:	-3.00
Change % Today:	-0.76
Fifty Two Week High:	452.00
Fifty Two Week Low:	282.00
Market Capital:	194.57

Period & price data
Period	Price
Now:	392.00
3 Months ago:
6 Months ago:
1 Year ago:

Additional information
Additional	Information
Market:	LSE
Sector:	Pharmaceuticals & Biotechnology
Epic:	ASD
News:	Latest news
Web Site:	Axis-Shield
Other Articles:

Axis-Shield

Axis-Shield is focused on the development and manufacturing of in vitro diagnostic tests for use in clinical laboratories and at the point of care. In the laboratory sector Axis-Shield specialises in proprietary markers for diagnosis and management of critical illnesses such as cardiovascular and neurodegenerative diseases and rheumatoid arthritis.

Tuesday, January 06, 2009

Axis-Shield develops anti-CCP rheumatoid arthritis test for Abbott Laboratories

In-vitro diagnostics group Axis-Shield PLC said it has developed and manufactured a new assay for anti-CCP (cyclic citrullinated peptide) used in the early diagnosis of rheumatoid arthritis (RA), to run on Abbott Laboratories’ Architect family of automated immunoassay analysers.

Rheumatoid arthritis is a chronic autoimmune disease characterised by inflammation of the lining of the joints, causing pain and disability.

“The introduction of tests recognising anti-citrullinated protein antibodies has caused a revolution in rheumatology. The antibodies may occur in the blood long before the onset of symptoms and the anti-CCP test is superior to rheumatoid factor (RF) regarding diagnostic specificity for RA, and is often associated with potentially more severe disease course and outcome,” Dr Thomas Skogh at the Linkoping University Hospital in Sweden was cited as saying.

The new assay has been launched in non-US markets only and an application has been filed with the Food and Drug Administration for US marketing clearance.

Investors interested in Axis-Shield recently viewed

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.